{
    "root": "6a34f3f1-4b17-4864-97ec-405fffb45f20",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Metoprolol Tartrate",
    "value": "20250326",
    "ingredients": [
        {
            "name": "METOPROLOL TARTRATE",
            "code": "W5S57Y3A5L"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "metoprolol tartrate injection , usp indicated treatment definite suspected acute myocardial infarction hemodynamically stable patients reduce cardiovascular mortality used conjunction oral metoprolol maintenance therapy .",
    "contraindications": "parenteral products inspected visually particulate matter discoloration prior , whenever solution container permit . initiate treatment coronary care similar unit immediately patient ’ hemodynamic condition stabilized . begin treatment early phase intravenous three bolus injections 5 mg metoprolol tartrate injection ; give injections approximately 2-minute intervals . intravenous metoprolol tartrate injection , monitor blood pressure , heart rate , electrocardiogram . transition oral metoprolol : following metoprolol tartrate injection , transition patients oral formulation metoprolol . prescribing information oral metoprolol dose selection .",
    "warningsAndPrecautions": "5 ml single dose vials – containing 5 mg metoprolol tartrate , usp carton 10 vials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 0143-9873-10 carton 25 vials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 0143-9873-25 also available oversized vials ( 10 ml ) large mouth ( 20 mm ) carton 10 vials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 0143-9660-10 store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . protect light heat . freeze . retain carton time .",
    "adverseReactions": "hypersensitivity metoprolol tartrate injection related derivatives , excipients ; hypersensitivity beta blockers ( cross sensitivity beta blockers occur ) . metoprolol tartrate injection contraindicated patients heart rate < 45 beats/min ; second-and third-degree heart block ( unless functioning pacemaker present ) ; significant first-degree heart block ( pr interval ≥0.24 sec ) ; systolic blood pressure < 100 mmhg ; decompensated cardiac failure .",
    "indications_original": "Metoprolol Tartrate Injection, USP is indicated in the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy.",
    "contraindications_original": "Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. \n                  Initiate treatment in a coronary care or similar unit immediately after the patient’s hemodynamic condition has stabilized. \n                  Begin treatment in this early phase with the intravenous administration of three bolus injections of 5 mg of Metoprolol Tartrate Injection each; give the injections at approximately 2-minute intervals. During the intravenous administration of Metoprolol Tartrate Injection, monitor blood pressure, heart rate, and electrocardiogram. \n                  Transition to Oral Metoprolol: \n                  Following administration of Metoprolol Tartrate Injection, transition patients to an oral formulation of metoprolol. See prescribing information for oral metoprolol for dose selection.",
    "warningsAndPrecautions_original": "5 mL Single Dose Vials \n                     – each containing 5 mg of Metoprolol Tartrate, USP \n                  Carton of 10 vials.......................................................................................................................NDC 0143-9873-10 Carton of 25 vials.......................................................................................................................NDC 0143-9873-25\n                  \n                     \n                        Also available in oversized vials (10 mL) \n                     with large mouth (20 mm)\n                  Carton of 10 vials.......................................................................................................................NDC 0143-9660-10\n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and heat. Do not freeze.\n                  Retain in carton until time of use.",
    "adverseReactions_original": "Hypersensitivity to Metoprolol Tartrate Injection and related derivatives, or to any of the excipients; hypersensitivity to other beta blockers (cross sensitivity between beta blockers can occur). \n                  Metoprolol Tartrate Injection is contraindicated in patients with a heart rate <45 beats/min; second-and third-degree heart block (unless a functioning pacemaker is present); significant first-degree heart block (PR interval ≥0.24 sec); systolic blood pressure <100 mmHg; or decompensated cardiac failure."
}